Drug Profile
AZD 4282
Latest Information Update: 03 Apr 2006
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 02 Feb 2006 Discontinued - Phase-I for Neuropathic pain in Europe (PO)
- 08 Oct 2003 Phase-I clinical trials in Neuropathic pain in Europe (PO)
- 18 Jan 2002 Preclinical development for Neuropathic pain in Europe (PO)